© 1997 American Heart Association, Inc.
Articles |
Trophic Effect of Human Pericardial Fluid on Adult Cardiac Myocytes
Differential Role of Fibroblast Growth Factor-2 and Factors Related to Ventricular Hypertrophy
From the Laboratoire d'Anesthésiologie (S.C., A.M., D.P.), Département d'Anesthésie-Réanimation; U127 Institut National de la Santé et de la Recherche Médicale (M.-P.G., F.M., D.C., L.R., J.L.S.); the Laboratoire de Biochimie (J.P.), Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Institut Fédératif de Recherches "Circulation," Université Paris 7 Denis Diderot; and Unité d'Immuno-Allergie (C.F., J.-M.C.), Institut Pasteur, Paris, France.
Correspondence to Alexandre Mebazaa, MD, PhD, Département d'Anesthésie-Réanimation, Hôpital Lariboisière, 2, Rue A. Paré, 75475 Paris Cedex 10, France. E-mail amebazaa.lariboisiere{at}invivo.edu
Abstract Pericardial fluid (PF) may contain myocardial growth factors that exert paracrine actions on cardiac myocytes. The aims of this study were (1) to investigate the effects of human PF and serum, collected from patients undergoing cardiac surgery, on the growth of cultured adult rat cardiac myocytes and (2) to relate the growth activity of both fluids to the adaptive changes in overloaded human hearts. Both PF and serum increased the rate of protein synthesis, measured by [14C]phenylalanine incorporation in adult rat cardiomyocytes (PF, +71.9±8.2% [n=17]; serum, +14.9±6.5% [n=13]; both P<.01 versus control medium). The effects of both PF and serum on cardiomyocyte growth correlated positively with the respective left ventricular (LV) mass. However, the magnitude of change with PF was 3-fold greater than with serum (P<.01). These trophic effects of PF were mimicked by exogenous basic fibroblast growth factor (FGF2) and inhibited by anti-FGF2 antibodies and transforming growth factor-ß (TGF-ß), suggesting a relationship to FGF2. In addition, FGF2 concentration in PF was 20 times greater than in serum. On the other hand, the LV mass–dependent trophic effect, present in both fluids, was independent of FGF2 concentration or other factors, such as angiotensin II, atrial natriuretic factor, and TGF-ß. These data suggest that FGF2 in human PF is a major determining factor in normal myocyte growth, whereas unidentified LV mass–dependent factor(s), present in both PF and serum, participates in the development of ventricular hypertrophy.
Key Words: protein synthesis • growth factor • serum • heart • human cardiomyopathy
This article has been cited by other articles:
 |
|
 |
|
  O. M. Gutierrez, J. L. Januzzi, T. Isakova, K. Laliberte, K. Smith, G. Collerone, A. Sarwar, U. Hoffmann, E. Coglianese, R. Christenson, et al. Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease Circulation, May 19, 2009; 119(19): 2545 - 2552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Kardami, Z.-S. Jiang, S. K Jimenez, C. J Hirst, F. Sheikh, P. Zahradka, and P. A Cattini Fibroblast growth factor 2 isoforms and cardiac hypertrophy Cardiovasc Res, August 15, 2004; 63(3): 458 - 466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Detillieux, F. Sheikh, E. Kardami, and P. A. Cattini Biological activities of fibroblast growth factor-2 in the adult myocardium Cardiovasc Res, January 1, 2003; 57(1): 8 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. R. Hermans, H. van Essen, H. A. J. Struijker-Boudier, R. M. Johnson, F. Theeuwes, and J. F. M. Smits Pharmacokinetic Advantage of Intrapericardially Applied Substances in the Rat J. Pharmacol. Exp. Ther., May 1, 2002; 301(2): 672 - 678. [Abstract] [Full Text] [PDF]
|
|